Last reviewed · How we verify
Ozempic®
Ozempic activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose levels in type 2 diabetes.
Ozempic activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose levels in type 2 diabetes. Used for Type 2 diabetes mellitus, Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease.
At a glance
| Generic name | Ozempic® |
|---|---|
| Also known as | semaglutide |
| Sponsor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R (glucagon-like peptide-1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Ozempic (semaglutide) is a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a hormone that regulates blood sugar. It stimulates pancreatic beta cells to release insulin in response to elevated glucose, delays stomach emptying to reduce postprandial glucose spikes, and acts on the brain to suppress appetite and food intake. These combined effects improve glycemic control and promote weight loss.
Approved indications
- Type 2 diabetes mellitus
- Cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Hypoglycemia
Key clinical trials
- A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes (NA)
- Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
- A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China
- A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment
- Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists (PHASE4)
- Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®
- UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study (PHASE2)
- Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ozempic® CI brief — competitive landscape report
- Ozempic® updates RSS · CI watch RSS
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. portfolio CI